Provided by Tiger Trade Technology Pte. Ltd.

PMV Pharmaceuticals

1.19
-0.0900-7.03%
Post-market: 1.230.0395+3.32%19:31 EST
Volume:486.94K
Turnover:595.87K
Market Cap:63.32M
PE:-0.75
High:1.31
Open:1.31
Low:1.18
Close:1.28
52wk High:1.84
52wk Low:0.8100
Shares:53.21M
Float Shares:36.20M
Volume Ratio:1.78
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5845
EPS(LYR):-1.1382
ROE:-51.87%
ROA:-32.02%
PB:0.52
PE(LYR):-1.05

Loading ...

PMV Pharmaceuticals Reports Increased Quarterly Loss

TIPRANKS
·
Nov 13

Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating

TIPRANKS
·
Nov 13

Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential

TIPRANKS
·
Nov 12

PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)

TIPRANKS
·
Nov 12

PMV Pharmaceuticals reports third quarter loss as cash reserves fall to $129.3 million

Reuters
·
Nov 12

BRIEF-PMV Pharmaceuticals Q3 EPS USD -0.4

Reuters
·
Nov 12

Major Stakeholder Orbimed Advisors Sells Massive PMV Pharmaceuticals Shares!

TIPRANKS
·
Oct 28

OrbiMed Advisors LLC Reports Disposal of PMV Pharmaceuticals Common Shares

Reuters
·
Oct 28

PMV Pharmaceuticals Advances Cancer Treatment with Promising Study on PC14586

TIPRANKS
·
Oct 28

PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data

TIPRANKS
·
Oct 24

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GlobeNewswire
·
Oct 24

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire
·
Oct 14

OrbiMed Advisors LLC Reports Disposal of Common Shares of PMV Pharmaceuticals Inc

Reuters
·
Sep 13

PMV Pharmaceuticals (PMVP) Gets a Buy from TD Cowen

TIPRANKS
·
Sep 11

PMV Pharmaceuticals Reports Promising Phase 2 Trial Results

TIPRANKS
·
Sep 11

BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy

Reuters
·
Sep 11

PMV Pharmaceuticals Shares Rise 6.3% After Positive Cancer Therapy Trial Data

THOMSON REUTERS
·
Sep 10

PMV Pharmaceuticals Inc - Rezatapopt Nda Submission for Platinum Resistant/Refractory Ovarian Cancer Planned in Q1 2027

THOMSON REUTERS
·
Sep 10

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GlobeNewswire
·
Sep 10

PMV Pharmaceuticals Q2 EPS USD -0.41

Reuters
·
Aug 07